Topical or Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in NZW Rabbits

被引：0
|
作者：
Gum, Glenwood G. [1 ]
Janusz, John [2 ]
Soldo, Brandi [2 ]
Walker, Brian [2 ]
Buch, Akshay [2 ]
Pakola, Steve [2 ]
Peters, Kevin G. [2 ]
机构：
[1] Absorpt Syst, San Diego, CA USA
[2] Aerpio Pharmaceut, Cincinnati, OH USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2018年 / 59卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
2719
引用
收藏
页数：3
相关论文
共 7 条
  • [1] Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy
    Brigell, Mitchell G.
    Gonzalez, Victor H.
    Bell, Darren J.
    Khanani, Arshad M.
    Withers, Barbara
    Gambino, Laura
    Campochiaro, Peter A.
    Peters, Kevin G.
    Pakola, Steve
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [2] The Tie2 Activator AKB-9778, Used In Combination With Ranibizumab, Enhances Reduction Of Diabetic Macular Edema Compared To Ranibizumab Monotherapy
    Khanani, Arshad
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [3] TIE2 expression in hypertensive ICH and its therapeutic modulation with AKB-9778: Implications for brain vascular health
    Wu, Jingkun
    Wang, Hongbin
    Wang, Naizhu
    Wang, Zai
    Zhu, Qinghua
    EXPERIMENTAL NEUROLOGY, 2024, 374
  • [4] Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression
    Campochiaro, Peter A.
    Khanani, Arshad
    Singer, Michael
    Patel, Sunil
    Boyer, David
    Dugel, Pravin
    Kherani, Saleema
    Withers, Barbara
    Gambino, Laura
    Peters, Kevin
    Brigell, Mitchell
    OPHTHALMOLOGY, 2016, 123 (08) : 1722 - 1730
  • [5] By targeting Tie2/VE-PTP in Schlemm's canal, AKB-9778 lowers intraocular pressure via increasing outflow facility in mice
    Stamer, W. Daniel
    Li, Guorong
    Navarro, Iris D.
    Nottebaum, Astrid
    Vestweber, Dietmar
    Peters, Kevin G.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [6] The VE-PTP Inhibitor AKB-9778 Improves Antitumor Activity and Diminishes the Toxicity of Interleukin 2 (IL-2) Administration
    Li, Guanqiao
    Sachdev, Ulka
    Peters, Kevin
    Liang, Xiaoyan
    Lotze, Michael T.
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (07) : 237 - 243
  • [7] A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema
    Brigell, Mitchell G.
    Campochiaro, Peter A.
    Sophie, Raafay
    Tolentino, Michael
    Miller, Daniel
    Browning, David
    Boyer, David S.
    Heier, Jeffrey S.
    Peters, Kevin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
1